Human lactogenic hormones, including growth hormone (hGH), placental lactogen (hPL) and prolactin (hPRL), all bind the human lactogen receptor. Current data suggests that lactogen and receptor bind with a 1:2 ratio and the two binding reactions have affinities that differ by at least an order of magnitude. Current information suggests lactogens may be similar to hGH and the somatotropin receptor where binding is an ordered process. The ordered hGH mechanism was demonstrated by mutagenic studies, where mutation of Site 1 eliminated binding at Site 2, but mutation of Site 2 had no effect of Site 1 binding. These results documented a uni-directional interaction between the two somatotrophic sites of hGH. Similar studies have been difficult to perform with lactogens because of the low affinity of Site 2. In fact, until examined by surface plasma resonance techniques, binding at Site 2 has been difficult to consistently document. No detailed structural mechanism has been described that will account for the interaction between Sites 1 and 2 in any lactogen. Using biological assays for lactogenic activity, we have recently described a series of contiguous hydrophobic residues in hGH that may be the motif by which Site 1 interacts with Site 2. Mutation of these residues, which span from Site toward Site 2, severely reduced the activity at Site 2. The main goal of this application is to determine if this motif is responsible for the interaction between Sites 1 and 2 in hGH, hPL and hPRL. Specific Objective 1 will characterize and compare the nature of lactogen/receptor binding; determining if the two binding sites interact and the nature and degree of interaction. Characterization of the binding mechanism of hGH, hPL and hPRL must be completed before studies probing the structural motif can be interpreted. Specific Objective 2 will determine the physical nature of the motif that apparently conducts the communication between Sites 1 and 2 of hGH. These studies will determine the size of the motif and characterize the role of each member residue in the communication between the two receptor binding sites. Specific Objective 3 will determine the same or a similar motif is conserved and operation in hPL and hPRL.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK056117-03
Application #
6381584
Study Section
Biochemical Endocrinology Study Section (BCE)
Program Officer
Sato, Sheryl M
Project Start
1999-08-01
Project End
2003-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
3
Fiscal Year
2001
Total Cost
$188,168
Indirect Cost
Name
Ohio State University
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
DePalatis, Laura; Almgren, Colleen M; Patmastan, Jypji et al. (2009) Structure and function of a new class of human prolactin antagonists. Protein Expr Purif 66:121-30
Peterson, F C; Brooks, C L (2004) Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor. Protein Eng Des Sel 17:417-24
Sivaprasad, Umasundari; Canfield, Jeffrey M; Brooks, Charles L (2004) Mechanism for ordered receptor binding by human prolactin. Biochemistry 43:13755-65
Duda, K M; Brooks, C L (2003) Differential effects of zinc on functionally distinct human growth hormone mutations. Protein Eng 16:531-4
Schenck, E J H; Canfield, J M; Brooks, C L (2003) Functional relationship of serine 90 phosphorylation and the surrounding putative salt bridge in bovine prolactin. Mol Cell Endocrinol 204:117-25